Table 2.

TGFBR2 and IL12B SNPs associated with overall survival ( P -value <0.001) in ER-negative patients with chemotherapy

Chr	Gene	SNP	Minor allele	MAF	ER-negative patients who received adjuvant chemotherapy				ER-negative patients who did not receive adjuvant chemotherapy					ER-positive patients who received adjuvant chemotherapy
					Cases, number	Events, number	HR a (95% CI)	P -value	Cases, number	Events, number	HR a (95% CI)	P -value	P heterogeneity b	Cases, number	Events, number	HR a (95% CI)	P -value	P heterogeneity c
3	TGFBR2	rs1367610	C	0.14	1499	267	1.54 (1.22, 1.95)	3.08 × 10−4	834	155	0.78 (0.55, 1.13)	0.191	8.82 × 10−4	3151	376	0.88 (0.70, 1.10)	0.251	2.62 × 10−4
5	IL12B	rs2546892	A	0.17	1499	267	1.50 (1.21, 1.86)	1.81 × 10−4	835	155	0.99 (0.74, 1.33)	0.968	0.025	3151	376	0.99 (0.82, 1.20)	0.940	4.63 × 10−3
5	IL12B	rs2853694	C	0.51	1499	267	0.73 (0.61, 0.87)	3.67 × 10−4	835	155	1.06 (0.85, 1.33)	0.596	0.020	3151	376	0.95 (0.82, 1.10)	0.529	0.023

^aHR adjusted for age of diagnosis, tumor size, tumor grade, node status and nine principal components to account for population substructure and stratified by study. ^b P-value for test of heterogeneity between ER-negative breast cancer patients who received adjuvant chemotherapy and ER-negative breast cancer patients who did not receive adjuvant chemotherapy. ^c P-value for test of heterogeneity between ER-negative breast cancer patients who received adjuvant chemotherapy and ER-positive breast cancer patients who received adjuvant chemotherapy. TGFBR2, transforming growth factor, beta receptor II; SNP, single nucleotide polymorphism; ER, estrogen receptor; Chr, chromosome; MAF, minor allele frequency; HR, hazard ratio; IL12B, interleukin 12B; and CI, confidence interval.